ProPhase Labs, Inc.: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Mar 31, 2022 and accepted by EDGAR at Mar 31, 2022, 21:09 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $79.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | $37.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2021-01-01 to 2021-12-31 | $42.0m | us-gaap:GrossProfit |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $520.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | $9.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2021-01-01 to 2021-12-31 | $1.1m | us-gaap:InterestExpense |
| Income tax | 12 months2021-01-01 to 2021-12-31 | −$968.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-01-01 to 2021-12-31 | $6.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | $0.40 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | $0.41 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 18,393,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | −$13.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $4.2m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 12 months2021-01-01 to 2021-12-31 | $4.5m | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2021-01-01 to 2021-12-31 | $917.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-12-31 | $8.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $61.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $89.3m | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $15.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $30.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $58.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-008541. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.